Zydus receives final approval for Clonidine Hcl Injection from the USFDA

Zydus Cadila has received the final approval from the USFDA to market Clonidine Hcl Injection 0.1 and 0.5 mg/ml, 10 ml. Clonidine hydrochloride injection is a centrally-acting analgesic solution for use in continuous epidural infusion devices which is indicated in combination with opiates for the treatment of severe pain in cancer patients that is not adequately relieved by opioid analgesics alone.

Zydus receives final approval for Lansoprazole DR Capsules

Zydus Cadila has received the final approval form the US FDA to market Lansoprazole DR capsules in the strengths of 15mg and 30 mg. The drug falls in the anti-ulcerant segment.The drug falls under the anti-ulcerant segment.

The estimated sales in 2012 as per IMS for Lansoprazole Dr capsules was $501 million

The group now has 81 approvals and has so far filed 186 ANDAs since the commencement of filing process in FY04.